Back to Interventions
Substance / Medication

Gabapentin enacarbil

SNOMED 703122000UMLS C2700226

Overview

Clinical overview including description, indications, and evidence base is pending physician authorship or FDA SPL integration. Graph-derived relationship data is available below.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Postherpetic neuralgia
Bipolar disorder
Epilepsy
Seizure disorder
Localisation-related epilepsy
Phobic disorder

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

Creatinine

LOINC 2160-0

secondary

Sodium

LOINC 2951-2

secondary

Thyrotropin

LOINC 3016-3

secondary

Clinical Trials

91 trials linked to this intervention

91
Total Trials
16
Recruiting
33
With Results

Recent Trials

Double-Blind, Placebo-Controlled Trial of Vitamin E as Add-on Therapy for Children With Epilepsy

NCT00004637Phase 4Completed

Treatment Of Primary Generalized Tonic-Clonic Seizures With An Investigational New Drug

NCT00043901Phase 4Completed141 enrolled

Measurement Of Serum Levels Of Two Antiepileptic Drugs During Conversion In Patients With Epilepsy

NCT00043914Phase 4Completed72 enrolled

A Multicenter Comparative Trial of Zonisamide and Topiramate as Initial Monotherapy in Untreated Epilepsies

NCT00154076Phase 4Completed140 enrolled

Open Label Safety and Efficacy Study of Levetiracetam in Patients With Epilepsy

NCT00160654Phase 4Completed251 enrolled
View all 91 trials on ClinicalTrials.gov

Research Evidence

Published studies and systematic reviews

Sort:
Effect of Gabapentin Enacarbil on Individual Items of the International Restless Legs Study Group Rating Scale and Post-sleep Questionnaire in Adults with Moderate-to-Severe Primary Restless Legs Syndrome: Pooled Analysis of 3 Randomized Trials.
Ahmed Mansoor, Hays Ryan, Steven Poceta J et al. · Clin Ther · 2016
PMID: 27288210Meta-Analysis
Meta-analyses of dose-exposure relationships for gabapentin following oral administration of gabapentin and gabapentin enacarbil.
Chen Chao · Eur J Clin Pharmacol · 2013
PMID: 23743781Meta-Analysis
Effects of Gabapentin Enacarbil on Postoperative Pain After Hip and Knee Arthroplasty: A Placebo-controlled Randomized Trial.
Ayad Sabry S, Makarova Natalya, Niazi Azfar K et al. · Clin J Pain · 2022
PMID: 35132024RCT
Difference in background factors between responders to gabapentin enacarbil treatment and responders to placebo: pooled analyses of two randomized, double-blind, placebo-controlled studies in Japanese patients with restless legs syndrome.
Inoue Yuichi, Hirata Koichi, Hoshino Yuya et al. · Sleep Med · 2021
PMID: 34329897RCT
Gabapentin Enacarbil Extended-Release Versus Placebo: A Likely Responder Reanalysis of a Randomized Clinical Trial.
Laska Eugene M, Siegel Carole E, Lin Ziqiang et al. · Alcohol Clin Exp Res · 2020
PMID: 33460198RCTFull text (PMC)
Reduced response to gabapentin enacarbil in restless legs syndrome following long-term dopaminergic treatment.
Garcia-Borreguero Diego, Cano-Pumarega Irene, Garcia Malo Celia et al. · Sleep Med · 2019
PMID: 30772697RCT
The Effect of Gabapentin Enacarbil on Quality of Life and Mood Outcomes in a Pooled Population of Adult Patients with Moderate-to-Severe Primary Restless Legs Syndrome.
Avidan Alon Y, Lee Daniel, Park Margaret et al. · CNS Drugs · 2016
PMID: 27067343RCT
Gabapentin enacarbil and morphine administered in combination versus alone: a double-blind, randomized, pharmacokinetic, and tolerability comparison.
Chen Chao, Upward James, Arumugham Thangam et al. · Clin Ther · 2015
PMID: 25467190RCT
Efficacy of gabapentin enacarbil vs placebo in patients with postherpetic neuralgia and a pharmacokinetic comparison with oral gabapentin.
Backonja Miroslav M, Canafax Daniel M, Cundy Kenneth C · Pain Med · 2011
PMID: 21627766RCT
The effect of food with varying fat content on the clinical pharmacokinetics of gabapentin after oral administration of gabapentin enacarbil.
Lal R, Sukbuntherng J, Luo W et al. · Int J Clin Pharmacol Ther · 2010
PMID: 20137764RCT

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Specialists

Providers who commonly manage this intervention

Psychiatry Physician

Psychiatry & Neurology — Psychiatry

NUCC 2084P0800X
Find a Provider

Health Goals

Goals connected through associated conditions

Support Mental Wellness

Quick Facts

Type
Substance / Medication
Fully Specified Name
Gabapentin enacarbil (substance)
SNOMED CT
703122000
UMLS CUI
C2700226

Clinical Data

This intervention maps to 11 entities in the Healos knowledge graph.

6
Conditions
3
Biomarkers
1
Specialists
0
Symptoms
91
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.